trial

Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial

NCTId NCT00224315
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 24
Sponsored by Central Institute of Mental Health, Mannheim
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
24
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2003-11
Primary completion
—
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
ZiprasidoneRisperidone

Sponsors

Central Institute of Mental Health, MannheimLead Sponsor

Investigators

1
Mathias Zink, MDPrincipal Investigator

Sites

1 total
Mannheim, Germany

Facts & assertions

3 sourced
Enrollment
24
Phase
PHASE4
Status
COMPLETED
relationships
The graph out of here
drug
Ziprasidone
drug
Risperidone
drug
lead_sponsor
Central Institute of Mental Health, Mannheim
company
indication
Schizophrenia, Schizoaffective Disorder
indication
Schizophrenia
indication
Psychotic Disorders
indication
investigator
Mathias Zink, MD
person